APA (7th ed.) Citation

Canadian Agency for Drugs and Technologies in Health. (2017). Patient group input submissions Omalizumab (Xolair) for asthma, severe persistent. Canadian Agency for Drugs and Technologies in Health.

Chicago Style (17th ed.) Citation

Canadian Agency for Drugs and Technologies in Health. Patient Group Input Submissions Omalizumab (Xolair) for Asthma, Severe Persistent. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017.

MLA (9th ed.) Citation

Canadian Agency for Drugs and Technologies in Health. Patient Group Input Submissions Omalizumab (Xolair) for Asthma, Severe Persistent. Canadian Agency for Drugs and Technologies in Health, 2017.